Eli Lilly and Company Book Value 2011-2025 | LLY

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Eli Lilly and Company

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
78.7 B	64 B	49.5 B	48.8 B	46.6 B	2.7 B	10.9 B	11.7 B	14.1 B	14.6 B	15.4 B	17.6 B	14.8 B	13.5 B

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
78.7 B	2.7 B	28.8 B

Quarterly Book Value Eli Lilly and Company

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
101 B	89.4 B	75.6 B	71.9 B	63.9 B	57.9 B	54.8 B	53.2 B	49.5 B	47.5 B	-	46.9 B	48.8 B	48.2 B	47.8 B	46.8 B	46.6 B	46.6 B	46.6 B	46.6 B	39.3 B	39.3 B	39.3 B	39.3 B	43.9 B	43.9 B	43.9 B	43.9 B	45 B	45 B	45 B	45 B	38.8 B	38.8 B	38.8 B	38.8 B	35.6 B	35.6 B	35.6 B	35.6 B	36.3 B	37.1 B	37.1 B	37.2 B	35.2 B	35.2 B	35.2 B	35.2 B	34.4 B	34.4 B	34.4 B	34.4 B	33.7 B	33.7 B	33.7 B	33.7 B

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
101 B	33.7 B	44.7 B

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Amphastar Pharmaceuticals AMPH	732 M	$ 25.27	-2.43 %	$ 1.22 B	USA
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	106 M	$ 4.75	1.61 %	$ 788 M	Canada
Aclaris Therapeutics ACRS	156 M	$ 3.26	-3.12 %	$ 252 M	USA
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	39.5 M	-	-15.15 %	$ 60.3 M	Britain
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Aeglea BioTherapeutics AGLE	518 M	-	-	$ 1.01 B	USA
Kamada Ltd. KMDA	319 M	$ 7.03	0.14 %	$ 260 M	Israel
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Ascendis Pharma A/S ASND	-106 M	$ 220.27	4.81 %	$ 5 B	Danmark
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Enlivex Therapeutics Ltd. ENLV	23.6 M	$ 0.91	-5.01 %	$ 18.7 M	Israel
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 0.28	-2.28 %	$ 609 M	Israel
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.3	-3.51 %	$ 7.94 B	Australia
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
AstraZeneca PLC AZN	40.9 B	$ 89.78	-0.57 %	$ 96.9 B	Britain
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
Anika Therapeutics ANIK	271 M	$ 9.57	0.84 %	$ 140 M	USA
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	3.33 B	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	20.1 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	142 M	-	-7.31 %	$ 87 M	USA
Benitec Biopharma BNTC	97.3 M	$ 12.05	-7.06 %	$ 496 M	USA
Aytu BioScience AYTU	124 M	$ 2.34	2.59 %	$ 14.7 M	USA
Nymox Pharmaceutical Corporation NYMX	-6.78 M	-	-19.68 %	$ 18.4 M	Canada
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Aptorum Group Limited APM	11.8 M	$ 1.29	-3.01 %	$ 7.03 M	China
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Baudax Bio BXRX	-24.2 M	-	0.59 %	$ 63 K	USA
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Catalyst Biosciences CBIO	78.5 M	$ 14.01	-8.49 %	$ 922 M	USA
ChromaDex Corporation CDXC	46.1 M	-	-0.88 %	$ 598 M	USA
Axon Enterprise AXON	2.33 B	$ 566.18	-2.56 %	$ 42.9 B	USA
Cerus Corporation CERS	56.9 M	$ 2.16	0.47 %	$ 399 M	USA
Checkpoint Therapeutics CKPT	-12.6 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	29.3 M	-	-16.75 %	$ 25.8 M	USA
Clovis Oncology CLVS	-279 M	-	-7.23 %	$ 13 M	USA
Biogen BIIB	16.7 B	$ 174.42	1.11 %	$ 25.4 B	USA
BioVie BIVI	19 M	$ 1.42	-5.96 %	$ 2.1 M	USA
Celldex Therapeutics CLDX	747 M	$ 27.36	-2.09 %	$ 1.76 M	USA
Cortexyme CRTX	85.1 M	-	-1.05 %	$ 67.1 M	USA
Cellectar Biosciences CLRB	-13.8 M	$ 3.63	-3.97 %	$ 44.4 M	USA
Deciphera Pharmaceuticals DCPH	351 M	-	-	$ 2.18 B	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-683 M	$ 11.54	0.87 %	$ 746 M	USA